| Literature DB >> 26075554 |
Padmaja Subbarao1, Carlos Milla2, Paul Aurora3, Jane C Davies4, Stephanie D Davis5, Graham L Hall6, Sonya Heltshe7, Philipp Latzin8, Anders Lindblad9, Jessica E Pittman10, Paul D Robinson11, Margaret Rosenfeld12, Florian Singer13, Tim D Starner14, Felix Ratjen1, Wayne Morgan15.
Abstract
The lung clearance index (LCI) is a lung function parameter derived from the multiple-breath washout (MBW) test. Although first developed 60 years ago, the technique was not widely used for many years. Recent technological advances in equipment design have produced gains in popularity for this test among cystic fibrosis (CF) researchers and clinicians, particularly for testing preschool-aged children. LCI has been shown to be feasible and sensitive to early CF lung disease in patients of all ages from infancy to adulthood. A workshop was convened in January 2014 by the North American Cystic Fibrosis Foundation to determine the readiness of the LCI for use in multicenter clinical trials as well as clinical care. The workshop concluded that the MBW text is a valuable potential outcome measure for CF clinical trials in preschool-aged patients and in older patients with FEV1 in the normal range. However, gaps in knowledge about the choice of device, gas, and standardization across systems are key issues precluding its use as a clinical trial end point in infants. Based on the current evidence, there are insufficient data to support the use of LCI or MBW parameters in the routine clinical management of patients with CF.Entities:
Keywords: cystic fibrosis; lung clearance index; multiple-breath washout; pulmonary function tests
Mesh:
Year: 2015 PMID: 26075554 PMCID: PMC5466249 DOI: 10.1513/AnnalsATS.201501-021FR
Source DB: PubMed Journal: Ann Am Thorac Soc ISSN: 2325-6621